Immix Biopharma (NASDAQ:IMMX – Get Free Report) and Viking Therapeutics (NASDAQ:VKTX – Get Free Report) are both medical companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, valuation, earnings, dividends, analyst recommendations and risk.
Profitability
This table compares Immix Biopharma and Viking Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Immix Biopharma | N/A | -102.68% | -80.89% |
| Viking Therapeutics | N/A | -12.73% | -12.31% |
Analyst Ratings
This is a summary of current recommendations and price targets for Immix Biopharma and Viking Therapeutics, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Immix Biopharma | 0 | 0 | 1 | 0 | 3.00 |
| Viking Therapeutics | 0 | 0 | 11 | 2 | 3.15 |
Insider & Institutional Ownership
11.3% of Immix Biopharma shares are held by institutional investors. Comparatively, 76.0% of Viking Therapeutics shares are held by institutional investors. 48.9% of Immix Biopharma shares are held by company insiders. Comparatively, 4.7% of Viking Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.
Risk & Volatility
Immix Biopharma has a beta of 0.27, indicating that its share price is 73% less volatile than the S&P 500. Comparatively, Viking Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the S&P 500.
Valuation and Earnings
This table compares Immix Biopharma and Viking Therapeutics”s revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Immix Biopharma | N/A | N/A | -$15.43 million | ($0.85) | -2.65 |
| Viking Therapeutics | N/A | N/A | -$85.89 million | ($0.93) | -43.66 |
Viking Therapeutics is trading at a lower price-to-earnings ratio than Immix Biopharma, indicating that it is currently the more affordable of the two stocks.
Summary
Viking Therapeutics beats Immix Biopharma on 7 of the 12 factors compared between the two stocks.
About Immix Biopharma
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Receive News & Ratings for Immix Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immix Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
